Why HealthEquity (HQY) is a Top Growth Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • Feb 18, 2026

Reasons to Hold HealthEquity Stock in Your Portfolio for Now

HQY rides on strong HSA growth, AI-driven efficiency gains and solid Q3 results, though data security threats remain a key risk.

Zacks Investment Research • Feb 18, 2026

HealthEquity Delivers Record Q4 and Standout Fiscal 2026 Sales Metrics

DRAPER, Utah, Feb. 17, 2026 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the “Company”), the nation's largest health savings account (“HSA”) custodian by number of accounts and leading provider of complementary consumer-directed benefits (“CDBs”), today announced its HSAs, HSA Assets, and Total Accounts as of its fiscal year ended January 31, 2026. The Company also reaffirmed its guidance for fiscal 2026 and 2027, provided an updated HSA cash repricing schedule, and announced upcoming events and presentations.

GlobeNewsWire • Feb 17, 2026

Here's Why HealthEquity (HQY) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • Feb 13, 2026

Here's Why HealthEquity (HQY) is a Strong Growth Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research • Feb 2, 2026

BLCO vs. HQY: Which Stock Is the Better Value Option?

Investors looking for stocks in the Medical Services sector might want to consider either Bausch + Lomb (BLCO) or HealthEquity (HQY). But which of these two stocks is more attractive to value investors?

Zacks Investment Research • Jan 23, 2026

Winners & Losers: The ETF Playbook to Glide Trump's Great Healthcare Plan

Trump's Great Healthcare Plan redraws healthcare winners and losers - here's how ETFs like IHE could benefit as middlemen face pressure.

Zacks Investment Research • Jan 19, 2026

HealthEquity, Inc. (HQY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

HealthEquity, Inc. (HQY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 14, 2026

The Market's Not Diagnosing HealthEquity Accurately

HealthEquity remains a 'buy' despite a 10.2% drop after 2027 guidance disappointed the market. HQY's core HSA business continues robust account and asset growth, driving consistent revenue and profit expansion. Management projects 2027 revenue of $1.38–$1.41 billion and EBITDA margins of 43.8–44.3%, supporting a bullish outlook.

Seeking Alpha • Jan 14, 2026

HealthEquity (HQY) Moves to Buy: Rationale Behind the Upgrade

HealthEquity (HQY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research • Dec 10, 2025